本研究结果显示,两组患者的总有效率分别为56.7%和81.8%,其中CR率分别为6.7%和27.3%,显示三维适形放疗联合多西他赛近期疗效明显优于序贯放化疗。两组1、2年生存率分别63.5% (19/30)、79.4% (26/33)和40.0%(12/30)、54.4% (18/33),三维适形放疗联合多西他赛组比序贯放化疗组高出十多个百分点,中位生存期亦比其高出7.5个月,虽无统计学意义,仍显示提高局部控制可使患者的长期生存获益。研究结果因观察时间有限,远期疗效和并发症有待进一步随访。
综上所述, TP方案联合三维适形放疗治疗晚期非小细胞肺癌有比较好的疗效及安全性,可延长生存期,急性毒副反应可耐受。因此TP方案联合放疗治疗晚期非小细胞肺癌是一种积极有效的措施。
【参考文献】
[1] Vora SA, Daly BD, Blaszkowsky L, et al. High dose radiation therapy and chemotherapy as induction treatment for stage Ⅲnonsmall cell lung carcinoma[J].Cancer,2000,89 (9):19461952.
[2] 汤钊猷.现代肿瘤学[M].第2版.上海:上海医科大学出版社, 2000:611.
[3] Rosenzweig KE, Sim SE, Mychalczalk B. Electivenodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy [J]. Int J Radiat Oncol Biol Phys, 2001, 50 (3): 681685.
[4] 蒋国良.现代肿瘤放射治疗学[M].上海:上海科学技术出版社,2003:506.
[5] Nafata Y, Negoro Y, Aoli T, et al. Clinical outcomes of 3D conformal hypofractionated single highdose radiotherapy for one or two lung tumors using a stereotactic body frame[J]. Int J Radiat Oncol Biol Phys, 2002, 52(4):10411046.
[6] 周桂霞,陈国雄,赵卫东,等.立体定向放射治疗肺癌的临床探讨[J].解放军医学杂志,2001,26(3):225.
[7] 王绿化.局部晚期非小细胞肺癌的治疗进展[J].临床肿瘤学杂志, 2006, 11(5): 321324.
[8] Lechevalier T, Berllle J, Zalcberg JR,et al.Overview ofdocetaxel(taxotere)and cisplatin combination in non-small cell lung cancer[J]. Semin Oncol, 1999, 26 (3 Suppl11): 1318.
[9] 任振义,白春学,洪群英,等.泰索帝对Lewis肺癌放疗增敏作用的实验研究[J] .辐射研究与辐射工艺学报,2002, 20(3): 191195医学全.在线www.lindalemus.com.
[10] Zavros Y, Eaton KA, Kang W, et al. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma[J]. Oncogene, 2005, 24(14):23542366.
[11] Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin,and alphamethylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma[J]. Mod Pathol, 2005, 18(9):1217.
[12] 丁颖,张帆,杨帆, 等. 三维适形放疗联合多西紫杉醇化疗治疗局部晚期非小细胞肺癌的临床研究[J]. 广东药学院学报, 2008, 24(1): 185-87.
[13] Kiura K,Ueoka H, Segawa Y, et al. PhaseⅠ/Ⅱstudy of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cacer[J]. Br J Cancer, 2003, 89(5): 795802.